![](https://cdn.sanity.io/images/0vv8moc6/targetedonc/a42e7ec836f432e8ba0cc58c9c11e28e20cfe514-1920x1080.png?fit=crop&auto=format)
Mirvetuximab Soravtansine Shows Efficacy in Ovarian Cancer Despite Dose Adjustments
Patients with FRα-positive, platinum-resistant ovarian cancer demonstrated positive improvements in progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) with mirvetuximab soravtansine-gynx (Elahere) over investigator’s …